MarketCap
Facebook
X
Telegram
Ayala Pharmaceuticals ROA | AYLA
ROA Jährlich Ayala Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -489.29 | -97.88 | -65.78 | -88.72 | - | - | - | - | - | - | - | - |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -65.78 | -489.29 | -185.42 |
ROA Vierteljährlich Ayala Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -138.34 | -159.75 | -110.67 | -92.65 | -59.93 | -73.86 | -63.58 | -84.74 | -68.58 | -93.75 | -98.68 | -105.2 | -61.68 | -25.17 | -18.86 | -17.65 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quartalsentwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -17.65 | -159.75 | -79.57 |
ROA anderer Aktien in der Pharmaeinzelhändler
| Name | ROA | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Infinity Pharmaceuticals
INFI
|
-105.26 | - | -46.98 % | $ 3.57 M |  USA |
 |
VistaGen Therapeutics
VTGN
|
-143.49 | $ 0.19 | 3.33 % | $ 7.23 M | USA |
 |
Evelo Biosciences
EVLO
|
-177.72 | - | -14.46 % | $ 27.9 M | USA |
 |
Morphic Holding
MORF
|
-21.05 | - | - | $ 2.42 B | USA |
 |
Genocea Biosciences
GNCA
|
-59.31 | - | -15.0 % | $ 3.04 M | USA |
 |
Vir Biotechnology
VIR
|
-43.68 | $ 13.12 | -0.23 % | $ 1.82 B | USA |
 |
Voyager Therapeutics
VYGR
|
-47.46 | $ 1.76 | -3.84 % | $ 103 M | USA |
 |
Eiger BioPharmaceuticals
EIGR
|
-193.07 | - | -9.21 % | $ 2.55 M | USA |
 |
IGM Biosciences
IGMS
|
-73.69 | - | - | $ 76.9 M | USA |
 |
Merrimack Pharmaceuticals
MACK
|
-6.15 | - | - | $ 216 M | USA |
 |
Rubius Therapeutics
RUBY
|
-778.79 | - | -33.55 % | $ 7.81 M | USA |
 |
Mirati Therapeutics
MRTX
|
-61.6 | - | - | $ 3.3 B | USA |
 |
Allogene Therapeutics
ALLO
|
-45.9 | $ 0.9 | -2.95 % | $ 199 M | USA |
 |
InVivo Therapeutics Holdings Corp.
NVIV
|
-55.73 | - | -37.48 % | $ 476 K | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-104.83 | - | -9.72 % | $ 5.89 M | USA |
 |
ORIC Pharmaceuticals
ORIC
|
-31.66 | $ 8.99 | 0.84 % | $ 789 M | USA |
 |
Orchard Therapeutics plc
ORTX
|
-68.82 | - | 1.02 % | $ 90.8 M |  Britain |
 |
La Jolla Pharmaceutical Company
LJPC
|
19.42 | - | - | $ 154 M | USA |
 |
Oyster Point Pharma
OYST
|
-45.22 | - | - | $ 300 M | USA |
 |
Intercept Pharmaceuticals
ICPT
|
-3.76 | - | - | $ 643 M | USA |
 |
Chinook Therapeutics
KDNY
|
-32.72 | - | - | $ 2.6 B | USA |
 |
Lumos Pharma
LUMO
|
-83.75 | - | - | $ 35.3 M | USA |
 |
Syros Pharmaceuticals
SYRS
|
-97.86 | - | -8.44 % | $ 3.4 M | USA |
 |
NanoViricides
NNVC
|
-83.24 | $ 1.4 | -1.41 % | $ 28.3 M | USA |
 |
Gamida Cell Ltd.
GMDA
|
-46.76 | - | -18.25 % | $ 5.04 M |  Israel |
 |
GT Biopharma
GTBP
|
-349.79 | $ 3.92 | -1.01 % | $ 21.6 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
-249.92 | - | -74.18 % | $ 955 K | USA |
 |
Zentalis Pharmaceuticals
ZNTL
|
-47.43 | $ 1.88 | 4.17 % | $ 135 M | USA |
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
15.42 | $ 547.57 | -0.06 % | $ 140 B | USA |
 |
Codexis
CDXS
|
-29.75 | $ 0.97 | -2.6 % | $ 84.5 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Geron Corporation
GERN
|
-14.64 | $ 1.0 | 2.38 % | $ 667 M | USA |
 |
Biogen
BIIB
|
4.39 | $ 254.59 | 0.53 % | $ 37.3 B | USA |
 |
GlaxoSmithKline plc
GSK
|
10.29 | $ 50.63 | -1.18 % | $ 205 B | Britain |
 |
Edesa Biotech
EDSA
|
-53.11 | $ 2.26 | 11.88 % | $ 12.8 M | USA |
 |
Keros Therapeutics
KROS
|
25.74 | $ 9.51 | 1.93 % | $ 354 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-78.59 | $ 15.2 | 0.66 % | $ 983 M | USA |
 |
Fulcrum Therapeutics
FULC
|
-20.44 | $ 3.74 | 0.54 % | $ 237 M | USA |
 |
Immutep Limited
IMMP
|
-39.13 | $ 3.57 | 3.03 % | $ 5.2 B |  Australia |
 |
Ionis Pharmaceuticals
IONS
|
-10.82 | $ 28.37 | 0.62 % | $ 4.54 B | USA |
 |
Iovance Biotherapeutics
IOVA
|
-42.82 | $ 8.09 | 0.06 % | $ 2.89 M | USA |
 |
Evogene Ltd.
EVGN
|
-39.05 | $ 0.37 | -0.51 % | $ 2.91 M | Israel |
 |
Armata Pharmaceuticals
ARMP
|
-226.06 | $ 3.72 | -0.8 % | $ 135 M | USA |
 |
Axsome Therapeutics
AXSM
|
-26.55 | $ 148.5 | 5.34 % | $ 7.39 B | USA |
|
Champions Oncology
CSBR
|
-4.35 | $ 4.77 | 0.42 % | $ 66 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
-13807.03 | $ 10.7 | 1.13 % | $ 306 M | USA |
|
Forte Biosciences
FBRX
|
-83.81 | $ 76.99 | 0.03 % | $ 997 M | USA |
 |
Immunic
IMUX
|
-404.01 | $ 8.14 | 1.18 % | $ 1.27 B | USA |
 |
DiaMedica Therapeutics
DMAC
|
-53.39 | $ 9.67 | 1.06 % | $ 454 M | USA |